The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event ...

Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect ...

The announcement comes as part of WHO’s broader effort to reduce child mortality, particularly in low- and middle-income ...

Citing concerns about mRNA technology, the Trump administration has pulled funding for a vaccine, even though Moderna says it ...

A statewide immunization program for infants against respiratory syncytial virus (RSV), which began in 2024, has already ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Discover how monoclonal antibody immunisation in Spain was vastly more effective than maternal vaccination in the UK.